QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques
PURPOSE: This research work entails quality by design (QbD)-based systematic development of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil (OLM) with improved biopharmaceutical attributes.
METHODS: Quality target product profile (QTPP) was defined and critical quality attributes (CQAs) were earmarked. Solubility of drug was performed in various lipids for screening of them. NLCs were prepared by hot-microemulsion method using solid lipids, liquid lipids and surfactants with maximal solubility. Failure mode and effect analysis (FMEA) was carried out for identifying high risk formulation and process parameters. Further, principal component analysis (PCA) was applied on high risk parameters for evaluating the effect of type and concentration of lipids and surfactants on CQAs. Further, systematic optimization of critical material attributes (CMAs) was carried out using face centered cubic design and optimized formulation was identified in the design space.
RESULTS: FMEA and PCA suggested suitability of stearic acid, oleic acid and Tween 80 as the CMAs for NLCs. Response surface optimization helped in identifying the optimized NLC formulation with particle size ∼250 nm, zeta potential <25 mV, entrapment efficiency >75%, in vitro drug release >80% within 6 h. Release kinetic modeling indicated drug release through Fickian-diffusion mechanism.
CONCLUSIONS: Overall, these studies indicated successful development of NLCs using multivariate statistical approaches for improved product and process understanding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 44(2018), 3 vom: 01. März, Seite 407-420 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beg, Sarwar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2018 Date Revised 01.02.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03639045.2017.1395459 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277167663 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277167663 | ||
| 003 | DE-627 | ||
| 005 | 20231225013612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2017.1395459 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0923.xml |
| 035 | |a (DE-627)NLM277167663 | ||
| 035 | |a (NLM)29048242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beg, Sarwar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2018 | ||
| 500 | |a Date Revised 01.02.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: This research work entails quality by design (QbD)-based systematic development of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil (OLM) with improved biopharmaceutical attributes | ||
| 520 | |a METHODS: Quality target product profile (QTPP) was defined and critical quality attributes (CQAs) were earmarked. Solubility of drug was performed in various lipids for screening of them. NLCs were prepared by hot-microemulsion method using solid lipids, liquid lipids and surfactants with maximal solubility. Failure mode and effect analysis (FMEA) was carried out for identifying high risk formulation and process parameters. Further, principal component analysis (PCA) was applied on high risk parameters for evaluating the effect of type and concentration of lipids and surfactants on CQAs. Further, systematic optimization of critical material attributes (CMAs) was carried out using face centered cubic design and optimized formulation was identified in the design space | ||
| 520 | |a RESULTS: FMEA and PCA suggested suitability of stearic acid, oleic acid and Tween 80 as the CMAs for NLCs. Response surface optimization helped in identifying the optimized NLC formulation with particle size ∼250 nm, zeta potential <25 mV, entrapment efficiency >75%, in vitro drug release >80% within 6 h. Release kinetic modeling indicated drug release through Fickian-diffusion mechanism | ||
| 520 | |a CONCLUSIONS: Overall, these studies indicated successful development of NLCs using multivariate statistical approaches for improved product and process understanding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Solubility | |
| 650 | 4 | |a experimental design | |
| 650 | 4 | |a lipid nanoparticles | |
| 650 | 4 | |a nanomedicine | |
| 650 | 4 | |a quality by design | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Emulsions |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Polysorbates |2 NLM | |
| 650 | 7 | |a Stearic Acids |2 NLM | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 650 | 7 | |a Oleic Acid |2 NLM | |
| 650 | 7 | |a 2UMI9U37CP |2 NLM | |
| 650 | 7 | |a stearic acid |2 NLM | |
| 650 | 7 | |a 4ELV7Z65AP |2 NLM | |
| 650 | 7 | |a Olmesartan Medoxomil |2 NLM | |
| 650 | 7 | |a 6M97XTV3HD |2 NLM | |
| 700 | 1 | |a Saini, Sumant |e verfasserin |4 aut | |
| 700 | 1 | |a Bandopadhyay, Shantanu |e verfasserin |4 aut | |
| 700 | 1 | |a Katare, O P |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Bhupinder |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 44(2018), 3 vom: 01. März, Seite 407-420 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2018 |g number:3 |g day:01 |g month:03 |g pages:407-420 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03639045.2017.1395459 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2018 |e 3 |b 01 |c 03 |h 407-420 | ||